Company news
Crescent Biopharma, Inc. (NASDAQ:CBIO) news
Crescent Biopharma, Inc. news releases on 6ix. Latest, Oct 6, 2026: Crescent Biopharma Announces Grants of Inducement Awards
Press releases & updates
Crescent Biopharma Announces Grants of Inducement Awards
October 6, 2026
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
October 5, 2026
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 16, 2026
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
July 14, 2026
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
July 13, 2026
Crescent Biopharma to Present at June Investor Conferences
June 2, 2026
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 21, 2026
Crescent Biopharma to Present at May Investor Conferences
May 6, 2026
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
April 29, 2026
Crescent Biopharma Announces Grants of Inducement Awards
March 26, 2026
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 25, 2026
Crescent Biopharma to Present at March Investor Conferences
February 23, 2026
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
February 17, 2026
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
January 4, 2026
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
December 4, 2025
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
December 3, 2025
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
Crescent Biopharma to Present at November Investor Conferences
November 5, 2025
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 3, 2025
Crescent Biopharma to Present at September Investor Conferences
August 28, 2025
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
July 30, 2025
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
July 8, 2025